IlluminaILMN
About: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Employees: 9,300
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
56% more funds holding in top 10
Funds holding in top 10: 9 [Q2] → 14 (+5) [Q3]
23% more capital invested
Capital invested by funds: $14.9B [Q2] → $18.3B (+$3.43B) [Q3]
20% more first-time investments, than exits
New positions opened: 138 | Existing positions closed: 115
3% more funds holding
Funds holding: 754 [Q2] → 777 (+23) [Q3]
1% more repeat investments, than reductions
Existing positions increased: 268 | Existing positions reduced: 266
1.27% less ownership
Funds ownership: 89.38% [Q2] → 88.11% (-1.27%) [Q3]
12% less call options, than puts
Call options by funds: $174M | Put options by funds: $197M
Research analyst outlook
16 Wall Street Analysts provided 1 year price targets over the past 3 months
16 analyst ratings
Morgan Stanley Tejas Savant 42% 1-year accuracy 5 / 12 met price target | 19%upside $156 | Equal-Weight Reinstated | 12 Nov 2024 |
Stephens & Co. Mason Carrico 67% 1-year accuracy 14 / 21 met price target | 41%upside $184 | Overweight Maintained | 12 Nov 2024 |
Piper Sandler David Westenberg 57% 1-year accuracy 12 / 21 met price target | 42%upside $185 | Overweight Maintained | 11 Nov 2024 |
Baird Catherine Ramsey 67% 1-year accuracy 6 / 9 met price target | 6%upside $139 | Neutral Maintained | 6 Nov 2024 |
TD Cowen Dan Brennan 38% 1-year accuracy 9 / 24 met price target | 35%upside $177 | Buy Maintained | 5 Nov 2024 |
Financial journalist opinion
Based on 14 articles about ILMN published over the past 30 days
